Dolby Laboratories stock has had a tough run over the past few years, yet the valuation checks currently lean cheap and suggest the market may be pricing the business more pessimistically than those checks imply.

• Over the last 5 years, shareholders have seen the stock decline 43.1%, which points to a long stretch of weak returns that may already reflect a lot of caution.
• Future demand for Dolby Laboratories' audio and imaging technologies can support the case for the current price, while any slowdown in adoption by device makers or content providers may cap how much investors are willing to pay.
• The company screens as undervalued in 5 of 6 valuation checks, so the broader set of metrics leans toward the stock looking cheap rather than expensive.

The issue now is whether the current share price already reflects the weaker share returns, or if Dolby Laboratories still offers enough value to justify taking on the risks in the story.

Is Dolby Laboratories Still Cheap on Earnings?

The P/E ratio is a useful starting point for Dolby Laboratories because earnings remain a key driver of how investors value the business. Dolby Laboratories trades at about 20.4x earnings, which sits below the broader software industry average of roughly 29.3x and also below the peer group average of around 34.6x. On headline comparison, the stock changes hands at a lower earnings multiple than many similar software companies.

A tailored fair P/E ratio for Dolby Laboratories that takes into account its margins, risk profile and size sits closer to 22.7x. That is still above where the shares currently trade, which leaves a gap between the current market pricing and what this framework suggests investors might usually pay for these earnings. For readers weighing Dolby Laboratories today, the P/E comparison suggests that the market is applying a noticeable discount to the stock relative to sector norms and this fair value benchmark.

On the P/E multiple, Dolby Laboratories stock appears undervalued compared with both its tailored fair ratio and the wider software sector.

The Dolby Laboratories Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Dolby Laboratories valuation puzzle leaves off and explain which combinations of growth, margins and earnings outcomes would need to occur for the stock to be worth materially more or less than it is today. Each narrative links a fair value estimate to a specific mix of potential catalysts and risks for Dolby Laboratories' business, allowing you to track over time which broad storyline is closer to reality on the Community page.

One of the top community narratives on Dolby Laboratories: 42% undervalued

"Advancements in spatial audio, AI-driven sound processing, and developer tools like Dolby.io are set to catalyze new direct-to-consumer and enterprise SaaS revenue streams..."

Do you think there's more to the story for Dolby Laboratories? Head over to our Community to see what others are saying!

The Bottom Line

For investors looking at Dolby Laboratories today, the market-multiple view points to a stock that currently screens as undervalued relative to sector peers and a tailored fair P/E range. The key question is whether that discount reflects temporary caution or a more lasting concern about how much earnings power Dolby Laboratories can sustain from its audio and imaging technologies. The crux of the debate is whether demand from device makers and content providers remains strong enough for the market to reconsider the current discount, or whether the lower multiple simply proves to be the right price for the risks involved.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.